Kornimate/medical-research-clean huggingface dataset:
experiential hiv testing increasing testing related knowledge and practice, and reduce stigma toward hiv of nurses.

Conditions: Hiv; HIV Testing

Summary: this is a randomized controlled trial design. the investigators plan to recruit about 60 to 70 emergency department nurses from a medical center in taipei, taiwan. after completing the paper consent form, these nurses will be randomly assigned to 2 groups, which are a control group and an experimental group. the pre-test includes the demographic data sheet, hiv testing related knowledge and practice scale, and the health care provider hiv/ aids stigma scale (hpass). all nurses will receive a learning material when they finish the pre-test. in addition, the experimental group will be provided a real hiv testing and counselling by a researcher. the post-test will be finished one month later of pre-test in the control group, and one month later while the intervention completed in the experimental group. the semi-structural interview will be performed to the experimental group to collect and analyze their opinion toward the experiential hiv testing.

this project aims to develop an intervention of "experiential hiv testing" and to verify the following effects on emergency nurses: (1) improve hiv testing related knowledge and practice; (2) reduce hiv-related stigma; (3) find out the possible demographic factors that might affect the effectiveness of experiential hiv testing. during the intervention, nurses can directly participate in the whole process of anonymous hiv testing in the role of who need to be screened, and pre- and post-testing counselling accompanied the education and discussion will also be provided to them by a researcher. through the above-mentioned measures, the knowledge and practices related to the hiv testing could be improved, and the stigma attitude toward hiv could be reduced through the self-reflection on the testing process.

Eligibility criteria:
inclusion criteria: - have registered nurse license and do clinical care in emergency department exclusion criteria: * have registered nurse license but doesn't do clinical care, likes head nurse. * do clinical care in emergency department but doesn't have registered nurse license, like volunteers or assistant nurse. * have experienced non-occupational hiv testing. * had been a nurse in hiv/aids-focus ward or hiv/aids case manager.

Keywords: stigma knowledge education, nursing situated learning
gi fluids collection for an ex-vivo development of ingestible capsule devices with real time biosensors

Conditions: Chronic Inflammatory Small Bowel Disease

Summary: up to 500 subjects undergoing standard endoscopy / pouchoscopy, or having ileostomy or colostomy bags or having an ileal pouch and who meet the eligibility criteria will be enrolled to this study during up to three years at up to 4 clinical sites. gi fluids samples will be collected from: (i) fluids suctioned during standard endoscopy procedures / pouchoscopy, (ii) from ileostomy/colostomy bags removed for bag replacement and (iii) from stool samples collected by patients after pouch surgery.

up to 500 subjects undergoing standard endoscopy / pouchoscopy, or having ileostomy or colostomy bags or having an ileal pouch and who meet the eligibility criteria will be enrolled to this study during up to three years at up to 4 clinical sites. gi fluids samples will be collected from: (i) fluids suctioned during standard endoscopy procedures / pouchoscopy, (ii) from ileostomy/colostomy bags removed for bag replacement and (iii) from stool samples collected by patients after pouchsurgery. the samples will be collected into sealed plastic containers, clearly labeled with "biohazard" stickers and patient's code and be kept on ice for up to 30min and then freezed in -20deg to -80deg. characterization and quanification of small molecules- and protein biomarkers of gi diseases such as ibd will be performed.

Eligibility criteria:
inclusion criteria: * subjects ages 18-75 years * subjects referred to endoscopic procedures gastroscopy, esophagogastroduodenoscopy (egd), colonoscopy, single balloon or double balloon enteroscopy or subjects having ileostomy or colostomy bags or subjects having an ileal pouch * subjects agree to sign consent form exclusion criteria: * patients has any medical condition that requires special handling of body fluids beyond routine infection control measures (i.e. standard surgical gloves)
safety and efficacy of lubiprostone in pediatric patients with constipation

Conditions: Constipation

Summary: the primary purpose of this study is to evaluate the safety and efficacy of lubiprostone in a pediatric population with constipation, including the pharmacokinetics of lubiprostone, in a subset of patients.


Eligibility criteria:
inclusion criteria: * less than 18 years of age * weight of at least 12 kg and capable of swallowing a capsule * able to refrain from use of medications known to treat or associated with constipation symptoms * stable fiber therapy or adhd therapy if using such medications * patient/caregiver able to complete daily diary * patient able to use recommended rectal and/or oral rescue medications if needed exclusion criteria: * constipation is associated with some medical, anatomic, physical, organic, or other condition * hirschsprung's disease or nonretentive fecal incontinence * untreated fecal impactions or impactions requiring digital manipulation * open gastrointestinal/abdominal surgery or laparoscopic surgery at the investigator discretion * organic bowel disorder, mechanical bowel obstruction, pseudo-obstruction, or unexplained weight loss * uncontrolled cardiovascular, liver or lung disease, neurologic or psychiatric disorder, other systemic disease, or abnormal laboratory tests at the investigator discretion * if female, is currently pregnant or nursing, or plans to become pregnant or nurse during the clinical study * sexually active males and females must utilize acceptable birth control methods * prior use of lubiprostone, amitiza, spi-0211, or ru-0211
study to evaluate the safety and efficacy of cj-12420 in patients with erosive esophagitis

Conditions: Erosive Esophagitis

Summary: the purpose of this study is to demonstrate the efficacy of cj-12420, once daily (qd), compared to esomeprazole in patients with erosive esophagitis classified as los angeles (la) classification grades a to d at week 8

this is a double blind, randomized, active controlled, phase 3 study. subjects will be randomly assigned to one of the two treatment groups (cj-12420 100 mg or esomeprazole 40 mg). all subjects will be asked to take two tablets at the same time each day throughout the study, and also all subjects will be asked to record daytime and nighttime symptom in a subject diary on a daily basis.

Eligibility criteria:
inclusion criteria: 1. subjects aged between 20 and 70 years 2. subjects who had experienced heartburn and regurgitation within 7 days before visit 1. entry into study also required that patients had experienced at least mild upper gastrointestinal symptoms on at least 2 days/week or at least moderate upper gastrointestinal symptoms on at least 1 day/week 3. endoscopically confirmed erosive esophagitis as defined by la classification grading system (a-d) within 14 days prior to randomization 4. subjects who is able to understand and follow the instructions and is willing to participate throughout the entire study 5. subjects who voluntarily signed written informed consent form 6. subjects who agreed to use medically acceptable contraceptives during the period of study. exclusion criteria: 1. subjects who cannot undergo egd 2. subjects who have esophageal stenosis, ulcer stenosis, gastroesophageal varices, barrett's esophagus, active gastric ulcer, gastrointestinal bleeding or malignant tumor confirmed by egd 3. subjects who have warning symptoms of malignant gastrointestinal tract such as odynophagia, severe dysphagia, bleeding, weight loss, anemia, or bloody stool 4. subjects with eosinophilic esophagitis 5. subjects diagnosed with primary esophageal motility disorder, ibs, ibd, etc. or with suspected ibs in the last 3 months 6. subjects who have a history of gastric acid suppression surgery or upper gastrointestinal, esophageal surgery 7. pregnant or lactating women 8. subjects with a history of clinically significant hepatic, renal, cardiovascular, respiratory, endocrine and cns system disorder 9. subjects with a history of hypersensitivity to the active ingredient or excipients of the study drug, etc. 10. subjects who participated in the other clinical trial within 4 weeks prior to randomization
preoperative nutritional assessment of the patients undergoing major gastrointestinal surgery and their immediate postoperative outcome

Conditions: Preoperative Nutritional Status and the Postoperative Outcome

Summary: it was a prospective observational study, where preoperative nutritional status and early postoperative complications \<30 days (infectious or noninfectious) were studied. the patients admitted between july 2015 to may 2017, who underwent major gi surgeries were included in the study. the study was designed to check if bmi and nri can predict the postoperative outcomes in these patients.

it was a prospective observational study. this study was done at nams, bir hospital, kathmandu, nepal between july 2015 to may 2017. all the patients who underwent major gi surgery, under general anesthesia, were included in the study. major was defined as surgery involving \>2hrs and excluded were an emergency major operation, gallstone disease operations, patients with cough, fever, and chest infections respectively. the sample size was calculated using the formula z2pq/d2. twice the number of sample calculated was taken into consideration and the maximum tolerable error was taken as 5%. bmi and nri were two independent categorical variables. the dependent variables were the postoperative outcome in terms of infectious and noninfectious complications. all the preoperative parameters were of the patients were recorded. the immediate postoperative complications were documented and categorized as infectious and noninfectious complications.

Eligibility criteria:
inclusion criteria: * all the patients who underwent major gi surgery, under general anesthesia, were included in the study. major was defined as surgery involving \>2hrs and exclusion criteria: * excluded were an emergency major operation, gallstone disease operations, patients with cough, fever, and chest infections respectively

Keywords: nutritional risk index body mass index postoperative complications length of hospital stay and cost.
injection management with betaferon: influence on adherence, patients satisfaction and health related outcomes (betapath)

Conditions: Relapsing-Remitting Multiple Sclerosis

Summary: aim of the betapath study is to evaluate whether the use of a personal digital assistant (pda) can improve the adherence of multiple sclerosis patients to a therapy with betaseron. the personal digital assistant pda functions as an electronic diary and as an injection reminder.


Eligibility criteria:
inclusion criteria: * outpatients with the diagnosis of multiple sclerosis and decision by the investigator to prescribe betaferon.the decision for treatment type and duration is taken before offering the patient the possibility to participate in the study. exclusion criteria: * patients, who do not meet the clinically isolated syndrome (cis) or relapsing/remitting multiple sclerosis (rrms) criteria, should not be included. * exclusion criteria must be read in conjunction with the german product information.

Keywords: multiple sclerosis interferon beta-1b
clinical study of chemoradiation followed by vipd in nasal natural killer (nk)/t-cell lymphoma

Conditions: Lymphoma, T-Cell

Summary: nasal nk/t-cell lymphoma is a peculiar clinico-pathologic subtype of non-hodgkin's lymphoma (nhl). although most patients present with stage i/ii, only 30-60% of the patients remain disease-free. the efficacy of the conventional anthracycline-based chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone \[chopp\]) has been unsatisfactory. the optimal treatment of localized nk/t-cell lymphoma has not been defined yet. the optimal dose, sequence, and multi-modality treatment with involved field radiotherapy still need to be refined. this trial is to evaluate the efficacy of concurrent chemoradiotherapy with cisplatin followed by vipd (etoposide, ifosfamide, cisplatin, dexamethasone) in localized nk/t-cell lymphoma patients.


Eligibility criteria:
inclusion criteria: * pathologically confirmed nk/t-cell lymphoma * localized (ann arbor stage i/ii) disease * at least one measurable lesion * age \> 18 * ecog performance status 0 - 2 * expected life span of at least 12 weeks * normal marrow function (hemoglobin ≥ 9.0 g/dl; absolute neutrophil count ≥ 1,500/mm3; platelet count ≥ 100,000/mm3) * normal liver function (total bilirubin \< 2x upper limit of normal \[uln\], transaminase \< 3x uln) * normal renal function (serum creatinine ≤ 1.5 mg/dl, creatinine clearance ≥ 50 ml/min) * written informed consent exclusion criteria: * other malignancies except for treated non-melanoma skin cancers and cervical cancer in situ * serious medical illnesses (congestive heart failure, angina, respiratory failure, and renal failure) * acute or active infection requiring intravenous (iv) antibiotics * pregnant, lactating women * previous history of chemotherapy or radiotherapy * concomitant medication that may influence the study drugs * allergic reaction to study drugs * grade 2 or greater peripheral neuropathy

Keywords: lymphoma, nk/t-cell
recombinant human endostatin(rh-endostatin) combine with radiotherapy in the treatment of hepatocellular carcinoma(hcc)

Conditions: Hepatocellular Carcinoma

Summary: hepatocellular carcinoma(hcc) is a high malignancy cancer which progress rapidly , and the rates of morbidity and mortality is very high in china. radiotherapy as a effective treatment is commonly used in unresectable hcc patients. preclinical models have shown that anti-angiogenesis medicine,such as rh-endostatin, can normalize the tumor vasculature to make it more efficient for oxygen delivery, which can enhance the radiosensitivity subsequently. this study is to evaluate the safety and efficacy of rh-endostatin combined with radiotherapy in the treatment of hcc.


Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed hepatocellular carcinoma,or radiographic indicative hcc with afp\>250ug/l * inoperable and untransplantable,child-pugh score a or b * ps score 0-1 * at least one measurable site(diameter \>20mm measured by ct or mri,\>10mm measured by helical ct scan. * no distant metastases * life expectancy longer than 3 months * willingness and ability to comply the study and signed informed consent. exclusion criteria: * not comply the designed treatment or change to other treatment * miss follow-up visits or have incomplete follow-up data * the efficacy will not be assessed if the patient withdrawal the treatment due to severe adverse events(sae),but sae will be recorded. * disease progression * patients request to withdraw * patients with iii hematologic or ⅳ nonhematologic drug related toxicity ,or sae

Keywords: rh-endostatin radiotherapy
early prediction of qfr in stemi-i

Conditions: ST Segment Elevation Myocardial Infarction

Summary: the study intends to provide important data on whether the noval method using quantitative flow ratio could predict microvascular dysfunction.

microvascular dysfunction (mvd) is a serious complication of pci, which happens frequently after stemi and always correlates with a poor prognosis. however, precise and simplified assessment of mvd is difficult, especially in the acute phase of stemi patients. resent studies suggested that ffr could be overestimated when mvd exists. but whether the overestimated value of ffr caused by cmr defined mvo could reflect microcirculation function is still unclear. this study is a retrospective study using stemi patients with tfg 2/3 of the infarct vessel on initial angiography and presumed culprit lesion ≥50% as the population. contrast-enhanced cmr was performed 5 days after pci as the reference standard.

Eligibility criteria:
inclusion criteria: * stemi patients treated with revasculation within 12 hours from onset of symptoms to pci time and received cmr 5 days afterwards. stemi was defined as a combination of the following: chest pain for more than 30min, electrocardiographic (ecg) changing with st segment elevation of \>2 mm in at least 2 precordial leads and \>1 mm in limb leads, and abnormal troponin levels or ckmb levels higher than twice the upper limit of normal. * patients with tfg 2/3 in the initial angiography of the culprit vessel. exclusion criteria: * patients with left bundle branch block in the presenting ecg, cardiogenic shock, pci or bypass surgery history. * patients with residual stenosis \<50%. * patients with unqualified coronary angiographic images with problems such as ostial lesion, severe vessel tortuosity and diffuse long lesions.

Keywords: stemi cardiac magnetic resonance
manual therapy and proprioceptive neuromuscular facilitation in field hockey players.

Conditions: Hockey Players Whith Lower Back and Hamstring Pain

Summary: introduction: field hockey is a contact sport. semiflexion asymmetric position, along with other theories such as the weakness of the extensor muscles of the back or hamstring injury, can be causes or aggravating that suelan hockey players suffer back pain. objectives: to observe the effectiveness of manual therapy techniques and post-isometric stretching (pnf) after three treatment sessions. in turn, know which of the two treatments have a greater benefit and longer. methods: the population consists of grass hockey players and senior category aged between 16-30 years. they were randomly divided into two treatment groups. group 1 corresponded to manual therapy techniques and group 2 to pnf stretching. the study duration for each subject was 5 sessions that included 3 treatment and 3 assessments. each evaluation consisted of goniometry, balance test using the sit and reach, and roland morris questionnaire.


Eligibility criteria:
inclusion criteria: * field hockey players (hh) (senior category). * between 16 and 30 years. * suffered injuries and microtraumatic not prevent them from sports. exclusion criteria: * subjects with structural abnormalities of the spine. * plantar alterations. * other moderate or severe musculoskeletal previous injuries in the last 6 months and prevented them make sport normally.

Keywords: low back manual therapy stretching
eravacycline combination therapy for mrab

Conditions: Pulmonary Infection; Pneumonia, Bacterial; Acinetobacter Baumannii

Summary: the goal of this observational study is to learn about the eravacycline combination therapy in multidrug-resistant acinetobacter gaumannii pneumonia. the main question is to evaluate the the effectiveness and safety. participants will be given eravacycline and polymyxin，or other antibiotcs that the investigator considered suitable. during the clinical trial, participants will be monitored for blood drug concentrations and drug concentrations in the elf (epithelial lining fluid。clinical efficacy rate and microbiological clearance rate will be assessed at the same time


Eligibility criteria:
inclusion criteria: 1. ≥18 years old; 2. meets the diagnostic criteria for pneumonia specified by the chinese medical association respiratory branch. 3. crab is identified or predominant pathogenic bacteria, and drug sensitivity test indicates that eravacycline is sensitive to the strain; 4. patients expected to receive eravacycline for ≥4 days; 5. has already signed the informed consent exclusion criteria: 1. pregnant or lactating; 2. concurrent intracranial infection, urinary tract infection, or bloodstream infection; 3. individuals in a moribund state; 4. the investigator believes there is any medical history, current condition, treatment, laboratory abnormalities, or other circumstances that may affect the trial results, interrupt the trial process (or the subject's inability to complete all trial requirements, operations, and visits), or increase the subject's risk with the experimental medication. patients with terminal illnesses or evidence of immediately life-threatening diseases are excluded; 5. patients with a history of allergic reactions to tetracyclines or any excipients in the investigational drug formulation

Keywords: eravacyline
impact of non-surgical periodontal treatment of mirnome

Conditions: Periodontitis

Summary: a double-blind randomized-controlled clinical trial is conducted in order to evaluate the impact of non-surgical periodontal treatment by means of minimally invasive approach minst or q-si (quadrantwise) approach in subjects with periodontitis on mirnome in gingival crevicular fluid

a double-blind randomized-controlled clinical trial is conducted in order to evaluate the impact of non-surgical periodontal treatment in subjects with periodontitis. 60 patients: 30 with periodontitis and 30 healthy controls. all the patients are assessed for clinical, periodontal, blood following of minimally invasive approach minst or q-si (quadrantwise). measurements are taken before and after initial periodontal treatment in the periodontal subjects.

Eligibility criteria:
inclusion criteria: * diagnosis of periodontitis exclusion criteria: * periodontal treatment * use of antibiotics, nsaids, and immunosuppressants during the last 6 months * pregnancy
nanochip technology in monitoring treatment response and detecting relapse in participants with diffuse large b-cell lymphoma

Conditions: Diffuse Large B-Cell Lymphoma; Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type; Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; High Grade B-Cell Lymphoma

Summary: this trial studies how well nanochip technology (immuno-tethered lipoplex nanoparticle \[iln\] biochip) works in monitoring treatment response and in detecting relapse in participants with diffuse large b-cell lymphoma. finding genetic markers for diffuse large b-cell lymphoma may help identify participants with this disease and help predict the outcome of treatment. it is not yet known how well iln biochip-based testing monitors treatment response or detects relapse in participants with diffuse large b-cell lymphoma.

primary objectives: i. determine whether iln biochip can be used to detect molecular marker(s) to monitor treatment response in patients with newly diagnosed diffuse large b-cell lymphoma (dlbcl). ii. determine whether iln biochip can promote early detection of disease relapse in patients with dlbcl. outline: participants' blood samples undergo iln biochip testing at diagnosis, before and after every course of chemotherapy, every 3 months for 2 years, and at relapse.

Eligibility criteria:
inclusion criteria: * histologically confirmed treatment naive dlbcl. subtypes including high grade b-cell lymphoma, not otherwise specified (nos) and de-novo dlbcl including germinal center b-cell type (gcb) and non-gcb subtypes. * intent to receive entire care (treatment and follow-up) at ohio state university (osu). * receiving treatment with curative intent. * receiving planned 6 cycles of chemotherapy. * ability to consent. exclusion criteria: * transformed lymphomas. * dlbcl with leukemic presentation. * primary central nervous system (cns) lymphoma. * participating in other clinical trial/ receiving experimental therapy. * patients with a "currently active" second malignancy that, in the opinion of the principal investigator, will interfere with patient participation, or confound data interpretation. * pregnancy (positive serum or urine pregnancy test) or breast feeding.